期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 65, 期 4, 页码 3066-3079出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c02008
关键词
-
资金
- National Natural Science Foundation of China [31900875, 81973177]
- State Key Laboratory of Natural and Biomimetic Drugs [K202004, K202118]
- Program for Science & Technology Innovation Talents in Universities of Henan Province [21HASTIT045]
SHP2, encoded by PTPN11, is a promising therapeutic target for cancer therapy. However, its multifaceted roles complicate drug discovery. Strategies targeting SHP2, including inhibitors, activators, and PROTAC degraders, have been developed. Protein-protein interactions between SHP2 and other adaptor proteins are also discussed. Target- and pathway-dependent combination strategies of SHP2 for cancer therapy are highlighted.
The protein tyrosine phosphatase SHP2 encoded by PTPN11 is a promising therapeutic target for cancer therapy, while the multifaceted roles of SHP2 complicate the drug discovery targeting SHP2. Given the biological significance of SHP2, strategies targeting SHP2 have been developed in recent years. To date, eight SHP2 inhibitors have advanced into clinical trials as mono- or combined therapy for treating solid tumors or adaptive resistant cancers. In this Perspective, we briefly summarize the strategies targeting SHP2 including inhibitors, activators, and proteolysis-targeting chimera (PROTAC) degraders. Besides, targeting the protein-protein interactions between SHP2 and other adaptor proteins is also discussed. Finally, we also highlight the target- and pathway-dependent combination strategies of SHP2 for cancer therapy. This Perspective may provide a timely and updated overview on the strategies targeting SHP2 for cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据